|
Boceprevir and telaprevir each show promising results in patients with hepatitis C. |
 |
 |
|
Boston.com: The analysis by FDA staffers used different criteria than Vertex used for assessing the hepatitis C cure rate based on the clinical trial data. Because of that, yesterday’s briefing document calculated the cure rate at 79 percent for the drug regimen Vertex is proposing — higher than the 75 percent the company reported last May. That compared to a 46 percent cure rate for patients taking the older drugs alone. A FDA briefing report prepared for Merck’s new drug calculated a cure rate of 66 percent for a similar population group.
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
